Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Completed · Phase 3

Conditions studied: Prostatic Neoplasms

In brief

This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

Key facts

Study ID
NCT00036556
Run by
Abbott
People needed
941
Starts
2001-06-01
Last updated by the study team
2007-08-15

Who can join

Age: 19 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.